Dec 30, 2025 • MarketBeat
SOMEWHAT-BULLISH
50,000 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Acquired by Oak Harvest Investment Services
Oak Harvest Investment Services has acquired 50,000 shares in Teva Pharmaceutical Industries (NYSE:TEVA), valued at approximately $1.01 million, according to its latest SEC filing. This acquisition comes as company insiders have been net sellers, disposing of 622,060 shares worth $17.08 million in the past 90 days. Analysts maintain a "Buy" consensus rating for TEVA with an average target price of $32.88, while some firms have recently raised their price targets.
Dec 30, 2025 • openPR.com
SOMEWHAT-BULLISH
Peptide Therapeutics Market 2025: Business Strategies
The global peptide therapeutics market is projected to reach USD 78,898.8 million by 2032, growing from USD 50,439.4 million in 2025 at a CAGR of 6.6%. This growth is attributed to rising industry demand, expanding applications, and ongoing technological advancements. The report provides a comprehensive analysis of market size, revenue trends, key growth factors, competitive landscape, and regional assessments, offering actionable insights for strategic decision-making.
Dec 30, 2025 • Finviz
SOMEWHAT-BULLISH
What Do Analysts Think About Teva Pharmaceutical Industries (TEVA)?
S&P Global Ratings upgraded Teva Pharmaceutical Industries Ltd.'s long-term issuer credit rating, and Moody's Ratings Agency revised its outlook to positive, citing the company's progress towards investment-grade status, improved adjusted leverage, and a return to revenue growth. Piper Sandler and Goldman Sachs subsequently raised their price targets for Teva, with Piper Sandler noting a shift towards a more appropriate peer group of larger cap biopharma companies. These upgrades and positive analyst revisions reflect growing confidence in Teva's operational and financial recovery.
Dec 29, 2025 • openPR.com
SOMEWHAT-BULLISH
Avascular Necrosis Market In-depth Insights, Business
The Avascular Necrosis Market is projected for substantial growth from 2025 to 2032, driven by increasing industry demand and technological advancements. A new report by Coherent Market Insights offers a detailed analysis of market size, revenue trends, key growth factors, and competitive landscape, providing actionable insights for stakeholders. Key players include Teva Pharmaceutical, Dr. Reddys Laboratories, and Novartis AG, with comprehensive segmentation by drug type, administration route, and distribution channel.
Dec 28, 2025 • MarketBeat
NEUTRAL
Voya Investment Management LLC Reduces Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA
Voya Investment Management LLC decreased its stake in Teva Pharmaceutical Industries Ltd. by 21.4% during the third quarter, selling 37,902 shares and retaining 139,235 shares valued at $2.81 million. Despite this, other institutional investors have been adding to their positions, and analysts maintain a largely bullish outlook with a consensus "Buy" rating and a target price of $32.88. Insider selling has also occurred, with key executives selling a significant number of shares in December.
Dec 27, 2025 • MarketBeat
SOMEWHAT-BULLISH
Greenwood Capital Associates LLC Raises Position in Teva Pharmaceutical Industries Ltd. $TEVA
Greenwood Capital Associates LLC has increased its stake in Teva Pharmaceutical Industries Ltd. by 17.9% in Q3, now owning 370,436 shares valued at $7.48 million. This increase comes as several analysts have raised price targets for Teva, with a consensus "Buy" rating and a target price of $32.88, despite recent insider selling totaling over $17 million. The company's stock shows a market cap of $36.55 billion and has experienced significant price performance throughout the year.